ATR 1072 in Participants With PRKAG2 Syndrome (NCT07738107) | Clinical Trial Compass
Not Yet RecruitingPhase 1/2
ATR 1072 in Participants With PRKAG2 Syndrome
37 participantsStarted 2026-10
Plain-language summary
ATR 1072 is an investigational medicine being studied in adults with PRKAG2 Syndrome. This study will evaluate the safety of ATR 1072 and how the body processes the drug. Researchers will also assess how ATR 1072 affects PRKAG2 activity and measures of heart disease.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Adults 18 to 65 years of age.
. Pathogenic, likely pathogenic, or variant of uncertain significance (VUS) in PRKAG2 confirmed by genetic testing.
. Clinical manifestations consistent with PRKAG2 Syndrome.
. Able and willing to comply with study procedures.
. Able and willing to undergo endomyocardial biopsy procedures (Part A)
Exclusion criteria
. Pregnancy or breastfeeding.
. Significant hepatic, renal, hematologic, or cardiovascular abnormalities that may increase study risk.
. NYHA Class IV heart failure or left ventricular ejection fraction \<45%.
. Recent clinically significant cardiovascular events or procedures.
. Prior treatment with prohibited investigational therapies or oligonucleotide therapies within protocol-defined washout periods.
. Any condition that, in the investigator's
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: From first dose through end of study (approximately 48 weeks per participant)